ABBV - AbbVie buys bowel disease drug developer Celsius for $250M
2024-06-27 09:48:45 ET
More on AbbVie
- AbbVie: 5 Reasons That Make A Buy Case
- AbbVie, Inc. (ABBV) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
- AbbVie: Turnaround Lurking After The Correction Pain (Upgrade)
- Genmab, AbbVie win FDA nod for relapsed follicular lymphoma therapy
- Cerevel Therapeutics sinks amid some worry on FTC review of AbbVie deal